Why Second Sight Medical Products, Inc. Soared Today

By Markets Fool.com

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Continue Reading Below

What: Shares of medical manufacturer and marketer of implantable visual prosthetics Second Sight Medical Products rose as much as 19% today after the company announced that all three of the centers approved to implant its Argus II Retinal Prosthesis System with reimbursement from the French Government were successful in their first implants.

The Argus II treats outer retinal degenerations, providing functional vision to patients who have lost their sight due to a rare, hereditary disease called retinal pigmentosa. The device is the first approved retinal prosthesis in the world.

So what: The Argus II is essential to Second Sight's business performance since the product is the company's primary source of revenue. In 2014, the French national healthcare reimbursement program "Forfait Innovation" named the Argus II as its first ever medical device for which it would fund implementation and associated hospital fees. As an expensive operation, and with just over 100 individuals receiving implants globally so far, today's successful first implementations is excellent news for potential patients and will drive business for the company. Thirty-six retinitis pigmentosa patients in France "stand to benefit from this life-changing technology with this first step in national reiumbursement," according to the company's press release this morning.

Now what: With just $2 million in sales in the trailing twelve months and a $300 billion market capitalization, Second Sight's market value already prices in significant growth, making the stock a speculative bet. And after today's nearly 20% rise, any incremental upside for Second Sight's business from today's news might have already been taken into account by the market.

The article Why Second Sight Medical Products, Inc. Soared Today originally appeared on Fool.com.

Continue Reading Below

Daniel Sparks has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.